MedTrace Logo

The Role of IL-22/IL-22BP Axis in Atopic Dermatitis

NCT04310189 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2022-12-12

No results posted yet for this study

Summary

Interleukin 22 (IL-22) is known to be regulated by IL-22 binding protein (IL-22BP), a soluble, inhibitory receptor. The potential role of IL-22BP in atopic dermatitis (AD) is mostly unknown and deserves further investigation. The main objective of this study is to better understand the potential protective role of IL-22BP through the assessment of its expression at the Messenger Ribonucleic Acid (mRNA) and protein levels in skin and serum which will be correlated to the severity of the diseases and through the identification of its cellular sources in lesions. The results of this study will help to correctly interpret the levels of IL-22 in AD and will potentially allow identifying biomarkers for patient stratification and predicting clinical outcomes to targeted therapeutic agents.

Conditions

Interventions

PROCEDURE

Biopsy

All patients will have a blood sample and 2 skin biopsies (2 mm diameter) in lesional and non lesional area

Sponsors & Collaborators

  • Plateforme CIMNA, Laboratoire d'Immunologie, Nantes University Hospital

    collaborator UNKNOWN

  • UCB Biopharma SRL

    collaborator INDUSTRY

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Sébastien BARBAROT · Nantes University Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-02
Primary Completion
2022-11-29
Completion
2022-11-29

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04310189 on ClinicalTrials.gov